Maintenance: The underexamined half of the GLP-1 story
GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
Newsletters and Deep Dive digital magazine
GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
The NIHR has revealed the first £45m in funding for projects that can bridge the translation gap in healthcare, focusing initially on community care.
UK Prime Minister Andy Burnham, who lost his father to Alzheimer's last week, has been urged to implement a "cancer-style" reform of dementia care.
Patients in the US with Sanfilippo syndrome type A have their first FDA-approved therapy, Ultragenyx Pharma's $3.9m one-shot gene therapy Fayuvi.
Once a treatment becomes available to the public, protecting patient safety remains a priority throughout its time on the market.
Editor's Picks
Newsletters and Deep Dive
digital magazine